truncated AUC [NCA / SHAM]

posted by drcampos  – Brazil, 2007-07-25 19:21 (6486 d 00:07 ago) – Posting: # 940
Views: 5,329

Dear Helmut,

Articles and Guidances have said that the use of truncated area under the curve could be a significant advantage for BE studies of drugs with long half-lives and low intrasubject variability. So, I would like to know why is not truncated AUC a good option to high intrasubject variability drug?

Regards,

Daniel Rossi de Campos
Brazil

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,668 registered users;
25 visitors (0 registered, 25 guests [including 5 identified bots]).
Forum time: 19:29 CEST (Europe/Vienna)

It is true that many scientists are not philosophically minded
and have hitherto shown much skill and ingenuity
but little wisdom.    Max Born

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5